 Puma Biotechnology publicized a licensing deal for Takedas alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. This has altered how I plan on managing my PBYI position. Puma announced the deal during one of the worst weeks for the market. I am looking to take advantage of the discounted prices. 